In vivo bioluminescence imaging has been used to monitor Staphylococcus aureus infections in preclinical models by employing bacterial reporter strains possessing a modified lux operon from Photorhabdus luminescens. However, the relatively short emission wavelength of lux (peak 490 nm) has limited tissue penetration. to overcome this limitation, the gene for the click beetle (Pyrophorus plagiophtalamus) red luciferase (luc) (with a longer >600 emission wavelength), was introduced singly and in combination with the lux operon into a methicillin-resistant S. aureus strain. After administration of the substrate D-luciferin, the luc bioluminescent signal was substantially greater than the lux signal in vitro. the luc signal had enhanced tissue penetration and improved anatomical co-registration with infected internal organs compared with the lux signal in a mouse model of S. aureus bacteremia with a sensitivity of approximately 3 × 10 4 cfU from the kidneys. finally, in an in vivo mixed bacterial wound infection mouse model, S. aureus luc signals could be spectrally unmixed from Pseudomonas aeruginosa lux signals to noninvasively monitor the bacterial burden of both strains. therefore, the S. aureus luc reporter may provide a technological advance for monitoring invasive organ dissemination during S. aureus bacteremia and for studying bacterial dynamics during mixed infections.
Results
Generation of a new lux expressing S. aureus strain. To generate an improved bioluminescent lux expressing S. aureus strain, the gene sequence luxCDABEG derived from the bioluminescent bacterial insect pathogen Photorhabdus luminescens was synthesized with Gram-positive ribosome binding sites at the start sites of each respective lux gene. This cassette has two strong promoters at the start called P CP25 and P CAP , followed by an excisable stem loop transcriptional terminator. Expression of the lux genes is driven by readthrough from these strong promoters. This complete lux cassette was cloned into plasmid pLL29 52 to generate plasmid pHC125 lux (Fig. 1A) . This plasmid was integrated at the φ11 attachment site on the chromosome of the CA-MRSA LAC strain AH1263 53 to generate the new bioluminescent strain AH4807 (lux). The construct is stable without selection and easily moved by bacteriophage transduction to other S. aureus strains such as CA-MRSA USA400 MW2 54 to generate strain AH4821 (lux) and MSSA Newman 55 to generate strain AH5016 (lux).
We compared the new AH4807 (lux) against the existing bioluminescent S. aureus strains USA300 LAC::lux 15 , LAC4303 (lux) 14, 56 and Xen36 (lux) 11 (Table 1) in terms of growth, luminescence output, and stability in vitro. For these comparison strains, USA300 LAC::lux was constructed by moving the original lux kanamycin resistant (Kan R ) cassette from strain Xen29 57 . LAC4303 (lux) has the lux construct on an integrated plasmid on the bacterial chromosome of USA300 LAC, and Xen36 (lux) has the lux construct inserted on a stable plasmid in the methicillin-sensitive S. aureus strain Wright. All four strains grow fairly similarly, with USA300 LAC::lux lagging slightly behind (see Supplemental Data, Fig. S1A ). LAC4303 (lux) generated the most bioluminescence during a 10-hour time course, followed by both AH4807 (lux) and Xen36 (lux) which behaved similarly over time (Fig. S1A) , and finally USA300 LAC::lux had the lowest luminescence output. LAC4303 (lux) is constructed with a temperature-sensitive plasmid called pRP1195 14 and we predicted this plasmid might undergo excision from the chromosome at lower temperatures. Indeed, we observed significant excision rates at 30 °C as determined by PCR ( Fig. S1B,C) , which were reduced at 37 °C and non-existent at 43 °C. Despite the instability, we did not observe a deleterious impact on overall LAC4303 (lux) luminescence at lower temperatures. The AH4807 (lux) plasmid pHC125 was stable at all temperatures as anticipated ( Fig. S1B,C) .
Generation of luc and lux + luc expressing S. aureus strains. Since the click beetle (Pyrophorus plagiophtalamus) red (CBR) luciferase (luc) has a longer emission wavelength of light (peak >600 nm [47] [48] [49] [50] [51] ) than lux (peak 490 nm 45 ) (Table 2) , we generated luc and lux + luc expressing CA-MRSA strains. The CBR luc gene was synthesized and cloned into the S. aureus shuttle vector pCM28 53 under the control of the hprK/lgt constitutive promoter, generating plasmid pHC123 CBR-luc ( Fig. 1B) . This plasmid was then transduced into the CA-MRSA LAC strain to generate the luc expressing strain AH4775 (luc) and into AH4807 (lux) to generate the lux + luc expressing strain AH4826 (lux + luc). In addition, the luc construct was also transduced in two divergent S. Table 2 . Peak wavelengths (nm) of lux versus CBR-luc + D-Luciferin substrate.
( Fig. 2A ) and bioluminescent signals ( Fig. 2B) were measured. LAC4303 (lux) was used as a comparison strain as it emits brighter bioluminescent signals than other existing lux strains (USA300 LAC::lux and Xen36 (lux)).
In the presence of 0.03, 0.15 or 0.30 mg of D-Luciferin, there was no difference in absorbance among all of the strains. However, in the presence of 0.60 mg D-Luciferin, from 10-14 hours there was higher absorbance of the lux expressing strains AH4807 and Xen36 (lux) than LAC4303 (lux) (P < 0.05) whereas the absorbance of USA300 LAC::lux, AH4775 (luc) and AH4826 (lux + luc) did not differ compared with LAC4303 (lux). At 1.20 mg of D-Luciferin, from 7-14 hours Xen36 (lux) and AH4775 (luc) had higher absorbance than LAC4303 (lux) (P < 0.05) whereas USA300 LAC::lux and AH4826 (lux + luc) had lower absorbance) compared with LAC4303 (lux). Irrespective of any effects of high concentrations of D-Luciferin (0.60 and 1.20 mg) on bacterial growth in vitro, all concentrations of D-Luciferin tested resulted in markedly increased bioluminescent signals with the luc expressing strains AH4775 (luc) and AH4826 (lux + luc) strains beginning at 6 hours, peaking at 7-9 hours and then slightly decreasing compared with the lower bioluminescent signals of LAC4303 (lux) (which had similar bioluminescent signals as all of the other lux expressing strains). To evaluate the new bioluminescent constructs in other S. aureus strains, lux, luc and lux + luc were expressed in the MW2 and Newman backgrounds and compared to LAC (see Supplemental Data, Fig. S2A,B ).
Taken together, although D-Luciferin at high concentrations had some effects on bacterial growth among the bioluminescent S. aureus strains, D-luciferin at all concentrations tested resulted in markedly increased bioluminescent signals only from the luc S. aureus strains, indicating bioluminescent signals produced by luc were a magnitude greater than those produced by lux in vitro. enhanced tissue penetration of luc compared with lux BLi signals in vitro. To evaluate the BLI signals produced by the lux versus luc constructs, AH4826 (lux + luc) was cultured overnight on bacterial culture plates. The plates were then imaged (IVIS Lumina IIII, PerkinElmer) with no filter (open) and with 520, 570, 620, 670, 710 and 790 nm emission filters in the absence (-) (lux signals only) or presence (+) (lux + luc signals) of D-Luciferin added to the surface of the plates (Fig. 3A) . With the open filter, D-Luciferin addition to AH4826 (lux + luc) colonies on the plates resulted in markedly higher BLI signals than in absence of D-Luciferin, suggesting that the light produced by luc greatly enhanced the BLI signals of lux alone. Furthermore, in the absence of D-Luciferin, the highest BLI signals were detected with the shortest wavelength emission filter (520 nm) and In vitro bacterial growth curves and bioluminescence signals. AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (all 1 × 10 4 CFU) were cultured in 96-well plates without (none) and with the addition of different concentrations (0.03-1.2 mg/240 µL TSB/well) of D-Luciferin for 0-14 hours and absorbance at 600 nm (A 600 ) (A) and bioluminescent signals (photons/0.1 second acquisition time) (B) were measured every 5 minutes on a plate reader (BioTek H1 Synergy) (n = 4 replicates with 2 iterations). the signals decreased with longer emission filters with no signals detected beyond the 620 nm emission filter. In contrast, in the presence of D-Luciferin, the lux + luc signals peaked with the 620 nm emission filter and the BLI signals decreased with shorter and longer emission filters away from this peak. Taken together, the BLI signals of AH4826 (lux + luc) in the absence and presence of D-Luciferin are consistent with the known peak wavelengths of 490 nm for lux 45 and 614 nm for CBR-luc in the presence of the D-Luciferin substrate 58 .
Given that CBR-luc signals were substantially greater and peaked at a much higher wavelength than those of lux, we evaluated whether the addition of D-Luciferin could enhance tissue penetration in vitro. This was accomplished by culturing AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) in 96-well plates without (none) or with increasing concentrations of D-Luciferin (0.03-2.4 mg) added to the wells (Fig. 3B ). Immediately prior to imaging the plates (IVIS Lumina III), different thicknesses of tissue (sliced cooked ham 5.25 to 21 mm) were placed on top of the plate covers. With no tissue placed on top of the plates, the BLI signals could be detected from all lux strains, including AH4826 (lux + luc) followed by LAC4303 (lux), Xen36 (lux), AH4807 (lux) and USA300 LAC::lux. With 5.25 mm of tissue placed on top of the plates, lux signals from only AH4826 (lux + luc), LAC4303 (lux) and Xen36 (lux) could be detected, and with 10.5 mm of tissue placed on top of the plates, no lux signals could be detected. With increasing concentrations of D-Luciferin added, both luc expressing strains AH4775 (luc) and AH4826 (luc + lux) had detectable BLI signals through 10.5 mm of tissue. Remarkably, with increasing concentrations of D-Luciferin, AH4826 (lux + luc) had BLI signals that could be detected through 15.75 and 21.0 mm of tissue. Taken together, the luc expressing strains AH4775 (luc) and AH4826 (luc + lux) in the presence of increasing concentrations of D-Luciferin had greater penetration of the BLI signals through tissue than any of the lux only expressing S. aureus strains. Moreover, strain AH4826 (luc + lux) had BLI signals that could be detected through greater than 2 cm of tissue. Both bacterial strains were inoculated intravenously at a 20-30% lethal dose (1 × 10 7 CFU) ( Fig. S3 ). On day 3 post-inoculation, the lux only representative in vivo BLI signals (i.e., no D-Luciferin administration) of AH4826 (lux + luc) and LAC4303 (lux) were relatively dim and could be only be detected from the bladder on the ventral sides of the mice (Fig. 4A ) and from the kidneys on the dorsal side of the mice (Fig. 4D ). To evaluate the luc in vivo BLI signals, on day 3 post-inoculation of AH4826 (lux + luc), D-Luciferin was administered subcutaneously and the mice were imaged for various time points up to 65 minutes. The administration of D-luciferin resulted in detectable in vivo BLI signals from the bladder as well as other internal organs in the abdominal cavity such as the kidneys and liver (no signals were detected from the chest) ( Fig. 4A,D) . Regarding the timeframe for optimal detection of in vivo BLI signals after D-Luciferin administration, the in vivo BLI signals increased over the first 10 minutes, peaking around 15 minutes and then remained at a similar level for up to 65 minutes, when imaging the mice was arbitrarily discontinued (Fig. 4B,E) . Without the addition of D-Luciferin, there was no statistical differences in the lux in vivo BLI signals from AH4826 (lux + luc) and LAC4303 (lux) on the ventral or dorsal sides of the mice (Fig. 4C ,F). The in vivo BLI signals from the abdominal cavity were significantly and markedly higher (155-fold on ventral side and 114-fold on dorsal side of the mice) with AH4826 (lux + luc) after D-luciferin administration compared with the lux only signals of AH4826 (lux + luc) (P < 0.01) ( Fig. 4C ,F). Taken together, administration of D-Luciferin to AH4826 (lux + luc)-infected mice resulted in a marked increase of the in vivo BLI signals from internal organs compared with the lux only BLI signals of AH4826 (lux + luc) or LAC4303 (lux). In addition, the optimal timeframe for in vivo BLI of the mice after D-Luciferin administration was ~15-25 minutes and this timeframe was used in subsequent experiments.
In vivo

In vivo BLi signals of lux versus luc in other animal models of S. aureus infection. Since AH4826
(lux + luc) after D-Luciferin administration resulted in enhanced in vivo BLI signals in the mouse model of S. aureus bacteremia in vivo ( Fig. 4 ), similar enhancement might occur in other preclinical models of S. aureus infection. A previously described S. aureus skin infection model was employed in which a bioluminescent S. aureus strain was inoculated intradermally (i.d.) into the dorsal back skin of mice and the ensuing in vivo BLI signals were measured (IVIS Lumina III) 22 . This model was performed with AH4826 (lux + luc) (1 × 10 8 CFU) ± D-Luciferin administration ( Fig. 5A,B ). There were no differences between the in vivo BLI signals ± D-Luciferin for the entire 10-day course of infection.
As an alternative preclinical S. aureus infection model, a S. aureus orthopaedic implant associated infection (OIAI) model in rabbits was also evaluated 59 . This model involved performing a medial parapatellar arthrotomy on the right rabbit knee, drilling a hole in the distal femur, inoculating a bioluminescent S. aureus strain into the intramedullary femoral canal and surgically placing of an orthopaedic-grade titanium locking peg into the canal prior to closure. The ensuing in vivo BLI signals from the infected post-surgical knees were measured noninvasively (IVIS Lumina III). This model was performed with AH4826 (lux + luc) (1 × 10 4 CFU) ± D-Luciferin administered prior to in vivo BLI ( Fig. 5C,D) . There was no difference between the in vivo BLI signals ± D-Luciferin for the entire 7-day course of the S. aureus OIAI.
To determine whether the AH4826 (lux + luc) bacteria maintained the luc plasmid construct after the in vivo infection, the infected skin tissue on day 10 ( Fig. 5B ) was homogenized and ex vivo CFU were cultured on plates overnight. BLI of the plates was performed ± the addition of D-Luciferin to the surface of the plates with no filter (open) and with 520, 570, 620, 670 and 710 nm emission filters (IVIS Lumina III) as in Fig. 3A (Fig. 5E ). The same pattern of BLI signals with and without the addition of D-Luciferin was observed as was with the in vitro mid-logarithmic phase bacteria in Fig. 3A , indicating that the ex vivo bacteria maintained the luc construct following the 10-day in vivo skin infection. Taken together, in both the S. aureus skin infection mouse model and (lux + luc) after D-Luciferin administration resulted in enhanced signal detection in the mouse model of S. aureus bacteremia in vivo from bacteria that disseminated to internal organs ( Fig. 4) , this model was used to determine whether 3D lux and luc signals could be co-registered with computed tomography (CT) images of the mice using the IVIS Spectrum-CT imaging system (PerkinElmer). The S. aureus bacteremia model with AH4826 (lux + luc) was performed as in Fig. 4 but with a lower (sub-lethal) inoculum (1 × 10 6 CFU) because the 3D IVIS Spectrum-CT imaging system has greater sensitivity for detecting in vivo BLI signals compared with the 2D IVIS Lumina III imaging system, which was used to acquire all other BLI data. On day 3 post-inoculation, the in vivo BLI signals of lux only (i.e., no D-Luciferin administration) resulted in dim bladder signals on the ventral sides of the mice and dim signals from the kidneys on the dorsal sides of the mice (Fig. 6A ). Additional representative images of 3 of the 10 mice in this experiment (with similar results) imaged on the 2D IVIS Lumina III are also provided ( Fig. S4 ). In contrast, after D-Luciferin administration, substantially increased in vivo BLI signals could be detected from the middle and lower back on the dorsal sides of the mice (Fig. 6A ). Indeed, the in vivo BLI signals after D-luciferin were 4-fold (day 1) to 15-fold (day 3) greater than without D-Luciferin on the ventral sides of the mice and 4-fold (day 1) to 70-fold (day 3) greater than without D-Luciferin of the dorsal sides of the mice (Fig. 6B ). On day 3, mice were euthanized and ex vivo CFU were enumerated after overnight culture of organ homogenates of the right kidney, left kidney, liver and heart. Overall, there were higher CFU isolated from the left and right kidneys (geometric mean = 2.89 × 10 4 CFU and 1.29 × 10 3 CFU, respectively) compared with CFU isolated from the liver (geometric mean = 8.97 × 10 2 CFU) or heart (geometric mean = 1.86 × 10 2 CFU) ( Fig. 6C ). and Movies S1 and S2) are shown of a single mouse that had a dim signal from the right kidney without D-Luciferin ( Fig. S5A and Movie S1) and a markedly increased signal from the right kidney after D-Luciferin administration ( Fig. S5B and Movie S2). In addition, representative 2D in vivo BLI images ( Fig. 6E [left panels]) and 3D in vivo BLI signals and CT image co-registration ( Fig. 6E [right panels]) of a single mouse that had no signals without D-Luciferin and had a detectable signal from the right axillary/chest regions after D-Luciferin administration ( Fig. S6 and Movie S3). Taken together, 3D in vivo BLI along with CT image co-registration was able to localize the source of the lux and luc signals. Importantly, administration of D-Luciferin to provide additional luc signals provided the new capability to visualize and co-register the source of in vivo BLI signals that could not be detected at all with the lux signals alone.
Sensitivity and duration of the in vivo BLi signals of the luc construct in the mouse model of S. aureus bacteremia. Since the in vivo BLI signals from strain AH4826 (lux + luc) after D-Luciferin administration were more than 100-fold greater than S. aureus strains expressing only the lux construct ( Fig. 4C ,F), the lower limit of sensitivity for in vivo BLI signals of AH4775 (luc) was determined. To accomplish this, the mouse model of S. aureus bacteremia was performed with the sub-lethal inoculum (1 × 10 6 CFU) of AH4775 (luc). At 16-hours post-intravenous inoculation, D-Luciferin was administered and after 20 minutes, in vivo BLI signals from regions of interests overlying the right and left kidneys on the dorsal sides of the mice were acquired (IVIS Lumina III) with a longer (5 minute) acquisition time. All mice were immediately euthanized, each kidney was harvested and ex vivo CFU were enumerated. The in vivo BLI and ex vivo CFU from each of the right and left kidneys were graphed on a dot plot ( Fig. 7A,B ). Using the IVIS Lumina III imaging system with the lower limit of detection (LOD) of 1 × 10 4 photons/s, there was a range of sensitivity in which the in vivo BLI signals reached the LOD for the mouse with 4.2 × 10 3 CFU isolated from the kidneys (as well as all mice with lower ex vivo CFU) whereas the in vivo BLI signals of the mouse with 3.3 × 10 4 CFU isolated from the kidneys could be detected (as well as all mice with higher ex vivo CFU) ( Fig. 7A,B) . Therefore, the LOD for in vivo BLI signals of AH4775 (luc) was approximately 3 × 10 4 CFU. Importantly, there was a high level of correlation between in vivo BLI and ex vivo CFU of AH4775 (luc) (correlation coefficient of determination of R 2 = 0.9924) ( Fig. 7B ). In addition, it is important to assess how long can the bioluminescent signals of AH4775 (luc) be detected in vivo. Therefore, as a proof-of-concept, the same mouse model of S. aureus bacteremia was performed in 2 representative mice with the sub-lethal inoculum (1 × 10 6 CFU) of AH4775 (luc) and the in vivo BLI signals from the dorsal sides of the mice were monitored weekly. In vivo BLI imaging was performed 20 minutes after D-Luciferin administration www.nature.com/scientificreports www.nature.com/scientificreports/ from the dorsal backs of the mice on a weekly basis and the experiment was arbitrarily ended at 3 weeks because bioluminescent signals were still detected in both mice (Fig. S7A) . At the 3-week time point, the mice were euthanized and ex vivo CFU from the kidneys were isolated and cultured on plates. The in vivo BLI and ex vivo CFU from each of the right and left kidneys were graphed on a dot plot (Fig. S7B) . The plates were then sprayed with D-Luciferin and imaged in the IVIS Lumina III and in one mouse 100% of the ex vivo CFU of AH4775 (luc) on the plates from both kidneys still emitted a bioluminescent signal whereas the other mouse had 96% and 64% of ex vivo CFU of AH4775 (luc) on the plates from the left and right kidneys, respectively, still emitted a bioluminescent signal (Fig. S7C) . These data indicate that the in vivo BLI signals from AH4775 (luc) could still be detected for at least 3 weeks of an in vivo bacteremia infection and the luc plasmid construct was relatively stable, as 64-100% of the ex vivo bacteria isolated still maintained the ability to produce bioluminescent signals.
Mouse model of a mixed S. aureus and P. aeruginosa wound infection mouse model. The AH4775 (luc) strain might also represent a technological advance to study the in vivo dynamics of the bacterial burden in a mixed infection model with different lux-expressing bacterial species, if the wavelengths of in vivo BLI signals from luc and lux signals could be spectrally unmixed. As a proof-of-concept, a mouse model of a mixed full-thickness wound infection with S. aureus and P. aeruginosa was modified from a previously established model in which the S. aureus inoculum was 10-fold higher than the P. aeruginosa inoculum 60, 61 . For this experiment, a 6-mm punch biopsy excisional wound was performed on the dorsal backs of mice and the wound bed was immediately inoculated with S. aureus AH4775 (luc) (2 × 10 6 CFU) and P. aeruginosa Xen41 (lux) (2 × 10 5 CFU) (PerkinElmer). After D-Luciferin (150 mg/kg s.c.) administration and performing in vivo BLI of the mice, it was determined that the 670 nm and 520 nm emission filters of the IVIS Lumina III were able to spectrally unmix the luc and lux signals, respectively, with no appreciable overlap of the bioluminescent signals. Therefore, in vivo BLI signals of AH4775 (luc) and Xen41 (lux) were monitored using these two filters over the course of the 7-day infection (Fig. 8A,B) . The in vivo BLI signals of AH4775 (luc) remained very stable with a slight decrease (12%) in signals from 6.82 × 10 5 ± 1.9 × 10 5 photons/s on day 1 to 6.02 × 10 5 ± 2.3 × 10 5 photons/s on day 7. In contrast, the in vivo BLI signals of Xen41 (lux) increased by approximately 2-fold from 1.0 × 10 6 ± 0.42 × 10 6 photons/s on day 1 to 2.44 × 10 6 ± 1.1 × 10 6 photons/s on day 3 and 1.83 × 10 6 ± 0.75 × 10 6 on day 7. It should be noted that the in vivo BLI signal intensity for AH4775 (luc) in the model was lower than Xen41 (lux), which was likely due to the use of the 670 nm filter (which was above the peak wavelength of the luc signal following D-Luciferin administration [ Table 2 ]) or due to less bioavailability of D-Luciferin at the site of the mixed infection in this in vivo wound model. On day 7, the mice were euthanized and ex vivo CFU were isolated and cultured on plates. The plates were then sprayed with D-Luciferin and imaged (IVIS Lumina III) using the same 670 nm and 520 nm emission filters to distinguish between CFU of AH4775 (luc) and Xen41 (lux), respectively (Fig. 8C) . The CFU were enumerated and there was a non-significant trend toward slightly increased CFU of AH4775 (luc) (geometric mean: 1.5 × 10 7 CFU) compared with Xen41 (lux) (geometric mean: 3.2 × 10 6 CFU) (P = 0.095) (Fig. 8D ). Taken together, these data indicate that a luc-expressing S. aureus strain could be used with a different lux-expressing bacterial strain (e.g., P. aeruginosa Xen41) to noninvasively and longitudinally monitor the dynamics of the bacterial burden of each bacterial strain in a mixed infection model.
Discussion
S. aureus bacteremia infections are a major clinical problem, especially since the mortality has remained extremely high and the treatment has been complicated by virulent and multi-drug resistant MRSA strains [3] [4] [5] [6] . To better study these infections in preclinical animal models, we generated new S. aureus strains in the well-studied community-acquired MRSA strain USA300 LAC background that express lux, CBR-luc or both lux and CBR-luc in the same strain, including AH4807 (lux), AH4775 (luc) and AH4826 (lux + luc), respectively. In AH4775 (luc) and AH4826 (lux + luc), the CBR-luc plasmid construct (with the luc gene is expressed under the strong constitutive S. aureus promoter hprK/lgt) was relatively stable, as it was maintained in the majority of progeny after a 3-week in vivo experiment. To the best of our knowledge, this is the first report that has successfully been able to generate a CBR-luc expressing S. aureus strain AH4775 (luc) and a dual lux and CBR-luc expressing S. aureus strain AH4826 (lux + luc).
We found that AH4807 (lux) with the newly generated luxCDABEG construct integrated in the S. aureus chromosome had relatively similar in vitro bacterial growth and bioluminescent signals as previously generated lux expressing S. aureus strains USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (Figs 2 and S1) . The lux and luc constructs could also be introduced into other S. aureus strains, including USA400 MW2 and Newman, demonstrating the broader utility of these constructs. While LAC4303 (lux) yielded the highest luminescence over time, the new AH4807 (lux) construct was more stably integrated in the chromosome (Fig. S1 ). Regarding tissue penetration, LAC4303 (lux) and Xen36 (lux) could be visualized through approximately 5 mm of tissue (sliced ham) whereas none of the signals from the lux expressing strains could be visualized through 10.5 mm of tissue. However, after adding D-Luciferin to cultures of AH4775 (luc) and AH4826 (lux + luc), there was markedly enhanced bioluminescent signals in the 96-well plate assay ( Fig. 2) and greatly increased tissue penetration, allowing visualization through >2 cm of tissue with AH4826 (lux + luc). Therefore, the addition of the luc construct provided the improved capability of detecting bioluminescent signals through an increased thickness of tissue to a much greater extent than any of the S. aureus lux expressing strains.
Given the increased bioluminescent signals and tissue penetration of AH4826 (lux + luc) in vitro, we investigated this particular strain in an in vivo model of S. aureus bacteremia. Without the administration of D-Luciferin, only dim in vivo BLI signals from lux could be detected from the bladder and kidneys on the ventral and dorsal sides of the mice, respectively. However, following administration of D-Luciferin, substantially increased in vivo BLI signals (up to 2 logs) could be visualized from the kidneys, liver and bladder on the ventral sides of the mice as well as increased signals from the kidneys on the dorsal sides of the mice. Most impressively, the 3D in vivo BLI co-registration with the CT imaging resulted in improved detection of in vivo BLI signals from the kidneys. Moreover, in a single mouse there was a focus of a bacterial dissemination in the right axillary/chest region that could only be detected after administration of D-Luciferin. Taken together, the administration of D-Luciferin and ensuing luc signals greatly enhanced the capability of detecting in vivo BLI signals from bacteria that disseminated to the organs and tissues in the mouse model of S. aureus bacteremia. In the bacteremia model, the luc-expressing S. aureus strain AH4775 (luc), following D-Luciferin administration, had a high level sensitivity of detection of the bacteria burden in the kidneys by in vivo BLI imaging, allowing as few as 3.3 × 10 4 CFU to be detected whereas 4,200 CFU could no longer be detected in the IVIS Lumina III. Furthermore, the in vivo BLI signals of AH4775 (luc) after D-Luciferin administration could be detected in the kidneys at least 3-weeks after wound mixed infection model by performing a 6-mm punch biopsy on the backs of mice and the wound beds were inoculated with S. aureus AH4775 (luc) (2 × 10 6 CFU) and P. aeruginosa Xen41 (lux) (2 × 10 5 CFU) (n = 5 mice). The mixed wound infection was followed for 7 days and CFU from the wounds were harvested, plated, cultured and enumerated. To distinguish between the in vivo BLI signals of AH4775 (luc) versus Xen41 (lux), the respective 670 nm and 520 nm emission filters (IVIS Lumina III) were used because there was no overlap between the luc and lux bioluminescent signals. the bacterial inoculation and most of ex vivo CFU maintained the ability to produce luc bioluminescent signals after the 3-week in vivo experiment (ranging from 64-100%). Nonetheless, for long-term in vivo studies, the in vivo BLI signals of the plasmid-based luc construct might underestimate the actual in vivo bacterial burden and therefore our future studies will evaluate whether the luc construct could be inserted into the bacterial chromosome for improved stability.
The improved ability to detect in vivo BLI signals in the mouse model of S. aureus bacteremia model is likely due to a combination of increased light production by the luc construct as well as the longer wavelength of light produced (614 nm) that enhanced tissue penetration. In the future, alternative substrates for the same luc construct in AH4775 (luc) and AH4826 (lux + luc) could be evaluated, such as the alkylaminoluciferins, aminoluciferins, naphthyl-based and AkaLumine-HCl luciferin analogs, luciferase substrates that can produce even longer wavelengths of light (up to and exceeding 730 nm), possibly allowing even greater tissue penetration than with D-Luciferin 58,62-64 . These other substrates might be particularly useful in mouse models of S. aureus bacteremia to detect the low bacterial CFU that are present in liver and heart (~10 2 CFU range) and potentially other disseminated organs and tissues. These analogs (administered systemically or perhaps locally [e.g., topical application or by local injection at the site of infection]) might also be able to enhance the signal of luc-expressing S. aureus strains over that of lux-expressing S. aureus strains, which might be especially useful in enhancing the signals in the mouse model of S. aureus skin infection and the rabbit orthopaedic implant model. These further enhancements and optimization of the luc signals will be the subject of our future work. In addition, the specific S. aureus luc construct developed in this study could be further modified with species-specific promoters and stable plasmid constructs so that it could be used in other Gram-positive bacteria, such as S. epidermidis (in which existing lux signals are dim, especially in biofilms 38, 46 ), Streptococcus pyogenes and Streptococcus pneumoniae to provide an alternative to lux expressing strains for better in vivo BLI detection in preclinical animal models of infection with these bacteria.
For in vivo BLI, the S. aureus luc signals were expected to be superior to lux signals because of the longer peak wavelength of the bioluminescent signals from CBR-luc that would have better tissue penetration. Indeed, CBR-luc has been shown to enhance in vivo BLI signals in preclinical mouse models with other microorganisms, including Listeria monocytogenes, Mycobacterium tuberculosis, and Candida albicans 47, 50, 51 . However, when AH4826 (lux + luc) was evaluated in a S. aureus skin infection mouse model and in a S. aureus OIAI rabbit model, the administration of D-Luciferin did not enhance the in vivo BLI signals produced by lux alone. Although the reason for this is not entirely clear, the bioluminescent signals from luc are dependent on the bioavailability of the D-Luciferin substrate, which was likely higher in the organs in the bacteremia model compared with the sites of the bacterial infection in the skin or OIAI models. This and other possibilities will be evaluated in our future work as they are beyond the scope of this initial report. Nonetheless, our results strongly suggest that a bioluminescent S. aureus strain such as AH4826 (lux + luc) would be extremely versatile as it would take advantage of signals from both lux and luc for improved in vivo BLI in different models of S. aureus infection.
It should also be mentioned that lux expressing bacteria and luc expressing bacteria can be used in conjunction with in vivo BLI as the different wavelengths of bioluminescent light from each strain can be spectrally unmixed. For S. aureus, the interactions of two or more bacteria by using luc versus lux expressing bacteria has important translational relevance as many S. aureus infections in humans are polymicrobial, including burns, chronic wounds, diabetic foot ulcers and surgical site infections 65 . Specifically, in various preclinical models of these polymicrobial infections, in vivo BLI could be used to simultaneous study S. aureus strain AH4775 (luc) along with another lux expressing bacterial strain (e.g., Pseudomonas aeruginosa, Streptococcus pneumoniae and Streptococcus pyogenes, Haemophilus influenzae or Enterococcus faecalis) to provide new insights into cooperative and competitive interactions between the different bacterial species with respect to bacterial growth, virulence and antibiotic susceptibility. As a proof-of-concept, we performed a mouse model of a mixed full-thickness wound infection with S. aureus AH4775 (luc) and P. aeruginosa Xen41 (lux). Using the 670 nm and 520 nm emission filters of the IVIS Lumina III, the S. aureus luc signals and P. aeruginosa lux signals could be spectrally unmixed, which permitted the noninvasive and longitudinal monitoring of the dynamics of the bacterial burden of each bacterial strain in this mixed infection model. Similar approaches have been previously used to study mutant versus wildtype M. tuberculosis strains during a pulmonary infection in mice 47 and to investigate Lactobacillus plantarum versus Lactococcus lactis persistence in intestinal compartments of mice 48 .
Taken together, the development of luc and lux + luc expressing S. aureus strains provided increased bioluminescent signals with deeper tissue penetration for improved in vivo BLI to study organ dissemination during a preclinical S. aureus bacteremia infection in mice. This study also provided the proof-of-concept of combining lux and luc constructs in the same bacterial strain AH4826 (lux + luc) to optimize the detection of in vivo BLI signals in different models of S. aureus infections. Therefore, the luc and lux + luc expressing S. aureus strains developed in this study represent a technological advance for improved in vivo BLI of preclinical S. aureus infection models to help provide new insights in the pathogenesis of the infection as well as evaluate novel therapeutic and diagnostic modalities.
Methods
construction of a lux expressing S. aureus strain. A luxCDABEG gene sequence, derived from the bioluminescent bacterial insect pathogen Photorhabdus luminescens (GenBank: MYFJ01000025.1), was synthesized (GenScript) with Gram-positive ribosome binding sites at the start of each respective gene, all common restriction enzyme sites were removed and P CP25 and P CAP promoters introduced at the start of this operon 66 . This DNA sequence was then amplified using Phusion DNA polymerase (NEB) and primers lux promoter (prom) 5′XbaI (GTT GAT TCT AGA GAT CTC GAG ATC TGC AAG ATC C) and luxG 3′EcoRI (GAA GTT GAA TTC TTA AAT AAA TTC GAA AGC ATC ACC ATA CAT G). The product was digested with XbaI and EcoRI before ligating into pLL29 52 to generate pHC125. The ligation reaction was transformed into E. coli DH5α, selecting www.nature.com/scientificreports www.nature.com/scientificreports/ with LB supplemented with 50 μg/mL spectinomycin. Positive clones were identified by bioluminescence, and the plasmids were isolated and electroporated into S. aureus RN4220 containing pLL2787 52 . S. aureus RN4220 colonies with chromosomally integrated pHC125 were selected on TSB supplemented with 1 μg/mL tetracycline. The integrated luxCDABEG cassette was then transduced into S. aureus strains USA300 LAC strain (AH1263 53 ), USA400 MW2 54 and Newman 55 using phage 11 67 , generating strain AH4807 (lux), AH4821 (lux) and AH5016 (lux), respectively (see Table 1 ).
construction of click beetle luciferase (luc)-expressing S. aureus strains.
A codon optimized version of click beetle red luciferase (luc) was synthesized (GenScript) and cloned into the S. aureus shuttle vector pCM28 53 under the control of the S. aureus hprK/lgt promoter in multiple steps. Beginning with pCM28 expressing DsRed (pHC48 68 ), the sarA promoter was replaced with the S. aureus hprK/lgt promoter. The region upstream of hprK was amplified from CA-MRSA LAC strain using primers Plgt 5′XbaI (GTT GTT TCT AGA GCC AAC TTG CAT TGT TTG TAG AA) and Plgt 3′ KpnI (GTT GTT GGT ACC CAA TTG TAT TTA TCC CTA CTC TTA CAT CTC). The resulting product was digested with XbaI and KpnI, and ligated into pHC48 digested with the same enzymes, generating pHC52. The DsRed gene was then replaced with the luc gene. Luc was amplified with primers Luc + RBS (CTT TAT AAG GAG GAA AAA CAT ATG GTA AAG CGT GAG AAA AAT GTC) and Luc 3′EcoRI (CAA CGA ATT CCT AGA TTA TTA CTA ACC GCC GG). An optimized ribosome binding site 69 was then built onto this sequence with a second round of PCR, using primers Luc + RBS 5′KpnI (GTT TGG TAC CTG ATT AAC TTT ATA AGG AGG AAA AAC ATA TGG T) and luc 3′EcoRI. The product was digested with KpnI and EcoRI, and ligated into pHC52 digested with the same enzymes, generating pHC123. The plasmid was transformed into E. coli DH5α, selecting on LB supplemented with 100 μg/mL ampicillin. The luc gene was confirmed by sequencing and the plasmid was then moved into S. aureus RN4220 by electroporation, selecting on TSB supplemented with 10 μg/mL chloramphenicol. pHC123 was then transduced into S. aureus LAC, MW2 and Newman to generate AH4775 (luc), AH5557 (luc), AH5556 (luc) respectively. In addition, the plasmid was transduced into the lux positive strains AH4807 (lux), AH4821 (lux) and AH5016 (lux) to generate AH4826 (lux + luc), AH5559 (lux + luc) and AH5558 (lux + luc), respectively. previously generated bioluminescent S. aureus strains. The previously generated lux expressing S. aureus strains were used. USA300 LAC::lux with the lux construct in the bacterial chromosome that was generated from the parent community-acquired MRSA USA300 LAC strain obtained from a skin infection outbreak in the Los Angeles County Jail and was kindly provided by Tammy Kielian (University of Nebraska) 15 . LAC4303 (lux) (also designated SAP430) with the lux construct in the bacterial chromosome that was generated from the parent JE2 strain, which is the MRSA USA300 LAC strain cured of its native plasmids 14, 56 . Xen36 (lux) with the lux construct integrated in a stable plasmid that was generated from the parent methicillin-sensitive S. aureus bacteremia isolate Wright (ATCC 49525) 11 .
Bacterial preparation. All S. aureus strains were streaked on tryptic soy agar (TSA) plates (tryptic soy broth
[TSB] plus 1.5% bacto agar [BD Biosciences, San Jose, CA]) and grown overnight at 37 °C. Single colonies were selected and cultured in TSB at 240 RPM at 37 °C in a shaking incubator overnight followed a 1:50 subculture at 37 °C in a shaking incubator for 2 hours to obtain mid-logarithmic phase bacteria. For strains AH4775 (luc) and AH4826 (lux + luc), to maintain the luc plasmid-based construct, all in vitro cultures were performed using TSB in the presence of 10 µg/mL of chloramphenicol. Bacteria were pelleted, washed and re-suspended in either TSB for in vitro experiments or PBS for in vivo experiments. Absorbance (A 600 ) was used to estimate CFU for in vitro and in vivo experiments, which were verified by overnight culture plating on TSA plates. P. aeruginosa Xen41 was streaked on LB plates (Luria-Bertani broth plus 1.5% bacto agar [BD Biosciences, San Jose, CA]). Single colonies were selected and cultured in LB at 240 RPM at 37 °C in a shaking incubator overnight followed a 1:50 subculture at 37 °C in a shaking incubator for 2 hours to obtain mid-logarithmic phase bacteria. Figure S1A and Figure S2 .
In vitro growth curves and lux versus luc bioluminescent signals for
All bioluminescent S. aureus strains were grown in TSB overnight at 37 °C in a shaking incubator at 240 rpm. Bacterial cells were harvested by centrifugation (5000 rpm for 10 minutes), washed twice in the same volume of phosphate buffered saline (PBS) and resuspended in TSB. Chloramphenicol (10 μg/mL) was added to cultures when needed to maintain plasmid stability. Absorbance at 600 nm (A 600 ) was adjusted to 0.05 for all strains. 200 µL of bacterial culture were added to black 96-well plates with clear bottoms (Corning) and plates were incubated at 37 °C with shaking in a humidified microtiter plate shaker (Stuart). A Tecan Infinite M Plex plate reader was used to periodically measure bacterial growth (A 600 ) and luminescence intensity (Integration time 1,000 milliseconds). For Fig. S1A , values from quadruplicate wells were averaged and luminescence was expressed as relative luminescence units corrected to normalized bacterial growth (A 600 ). The experiment was repeated three times with biological replicates. For Fig. S2 , values from triplicate wells without or with addition of different concentrations (0.125-5 mg/ml) of D-Luciferin (XenoLight D-Luciferin -K + Salt Bioluminescent Substrate, PerkinElmer) were averaged and luminescence was expressed as relative luminescence units (RLU). The experiment was repeated three times with biological replicates. chromosomal integration stability of the lux bioluminescent construct for Figure S1B,C. LAC4303 (lux) and AH4807 (lux) were grown in 5 mL of TSB at 37 °C in a shaking incubator at 240 rpm overnight. One mL was harvested by centrifugation (5000 rpm, 10 minutes), washed twice in the same volume of PBS and resuspended in 700 µL TSB. Cells were diluted up to 10 −6 and 100 µL were subsequently plated on three TSA plates; one plate was incubated at 43 °C, one at 37 °C and one at 30 °C for 18 hours. To determine whether plasmids are stably integrated into the chromosome, five randomly selected colonies from TSA plates incubated at 43 °C, 37 °C and 30 °C were resuspended in PBS, pelleted (5000 rpm, 10 minutes), resuspended in double distilled H 2 O (ddH 2 O) with 0.5 mg/mL lysostaphin (AMBI Products, LLC) and incubated for 45 minutes at 37 °C. 5 µL of the cell lysate was used per PCR reaction (Taq DNA Polymerase, NEB). PCR reactions were performed using primers shown in Fig. S1B , and all primer sequences are published 14, 52 . Loading dye (TriTrack, Thermo Scientific) was added to all PCR reactions and 6 µL of each PCR reaction were analyzed on a 1% agarose gel, which was stained in an ethidium bromide (Teknova) bath, destained in water and visualized with a UV Transilluminator (G:Box, Syngene) and GeneSys software (Syngene, Version 1.6.6.0). Original agarose gel images were color inverted, cropped and labeled using IrfanView software (Austria, Version 4.53) and Adobe Illustrator (USA, Version 23.0.3).
In vitro growth curves and lux versus luc bioluminescent signals. AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (all 1 × 10 4 CFU) were cultured in 96-well black polystyrene microplates with clear bottoms that were tissue culture (TC)-treated (Corning) without (none) and with the addition of different concentrations (0.03-1.2 mg/240 µL/well) of D-Luciferin (XenoLight D-Luciferin -K + Salt Bioluminescent Substrate, PerkinElmer) for 0-14 hours at 240 rpm at 37 °C. Absorbance (A 600 ) and bioluminescent signals (photons/0.1 second) were measured every 5 minutes on a plate reader (BioTek H1 Synergy) (n = 4 replicates with 2 iterations). All absorbance and bioluminescent signal measurements were blanked to control wells containing the same D-Luciferin concentration. In vitro lux versus luc BLi signal through tissue. AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (1 × 10 9 CFU) were cultured in 96-well black polystyrene microplates with clear bottoms that were TC-treated (Corning) without (none) and with the addition of different concentrations (0.03-2.4 mg/280 µL TSB/well) of D-Luciferin (PerkinElmer). To determine tissue penetration of the BLI signals, different thicknesses (5.25-21.0 mm) of sliced cooked ham (Lunch Mate) were placed on top of the plate covers prior to BLI. All plates were imaged for a 1 minute acquisition time at 37 °C (IVIS Lumina III) and representative images of the BLI signals are provided (n = 3 replicate wells for all conditions with 2 iterations).
In vitro lux versus luc
Animals (mice and rabbits).
All mouse and rabbit studies were approved by the Johns Hopkins University Animal Care and Use Committee according to the guidelines and regulations described in the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). All mice and rabbits were maintained and housed under specific pathogen-free conditions at our animal facility accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC) at Johns Hopkins. Six to 8 week-old female C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were used in all in vivo mouse experiments. Ten to 16 week-old male Dutch Belted rabbits (Robinson Services, Mocksville, NC) (~2 kg body weight) were used in all in vivo rabbit experiments.
Mouse model of S. aureus bacteremia. Mice were anesthetized (inhalation 2% isoflurane) and all hair on the dorsal and ventral skin was shaved with clippers. Anesthetized mice were inoculated intravenously (i.v.) with either a 20-30% lethal inoculum (1 × 10 7 CFU) or a sub-lethal inoculum (1 × 10 6 CFU) of LAC4303 (lux) or AH4826 (lux + luc) in a 100 μL volume of PBS using a 29-gauge insulin syringe via the retro-orbital vein. For the 1 × 10 7 CFU inoculum, on day 3 post-inoculation, in vivo BLI was performed on anesthetized mice (2% isoflurane) from the ventral and dorsal sides of the mice before (−5 minutes) and after injection (at the indicated time points between 0 and 65 minutes) of D-Luciferin (150 mg/kg administered subcutaneously [s.c.]) for a 1 minute acquisition time at 37 °C (IVIS Lumina III). For the 1 × 10 6 CFU inoculum, on days 1, 2 and 3 post-inoculation, in vivo BLI was performed on anesthetized mice (2% isoflurane) ± administration of D-Luciferin (150 mg/kg s.c. given 15-25 minutes prior to imaging) for a 1 minute acquisition time at 37 °C (IVIS Lumina III). Total flux (photons/s) was measured within an oval region of interest (2 × 4 cm) from the ventral and dorsal sides of the mice using Living Image software (PerkinElmer). To provide anatomical co-registration data, for the 1 × 10 6 CFU inoculum, in vivo BLI and simultaneous CT imaging were performed on day 3 post-inoculation on anesthetized mice (2% isoflurane) ± administration of D-Luciferin (150 mg/kg s.c. given 15-25 minutes prior to imaging) for a 3 to 15 minute acquisition time (depending on signal intensity using autoexposure) at 37 °C using firefly luciferase DLIT settings (600 nm, 620 nm, 640 nm filters) on an IVIS Spectrum-CT imaging system for both lux and luc signals (PerkinElmer). To determine the in vivo lower limit of sensitivity and duration of the in vivo BLI signals of AH4775 (luc), 6-week old of C57BL/6 female mice were inoculated intravenously with 1 × 10 6 CFU of AH4775 (luc). At 16-hours (sensitivity) or on a weekly basis up to 3-weeks post infection, mice were administered D-Luciferin (150 mg/kg s.c.) and after 20 minutes in vivo BLI was performed on the dorsal sides of the mice with a 5 minute acquisition time at 37 °C (IVIS Lumina III). Total flux (photons/s) from two separate oval region of interests (1.1 × 0.9 cm) overlying the right and left kidneys were measured using Living Image software (PerkinElmer). Mice were then immediately euthanized and the right and left kidneys were separately isolated, homogenized and plated overnight to enumerate the ex vivo CFU, as described below. The linear regression line and correlation coefficient of determination between in vivo BLI and ex vivo CFU were calculated using Prism (GraphPad, La Jolla, CA).
Mouse model of S. aureus skin infection. This mouse model of S. aureus skin infection was performed as previously described 22 . Briefly, the dorsal backs of anesthetized mice (2% isoflurane) were shaved and injected intradermally (i.d.) in the upper back skin with 1 × 10 8 CFU/100 μL PBS of AH4826 (lux + luc). On days 1, 3, 7 and 10, in vivo BLI was performed on anesthetized mice (2% isoflurane) ± administration of D-Luciferin (150 mg/kg s.c. given 15-25 minutes prior to imaging) for a 1 minute acquisition time at 37 °C (IVIS Lumina III). Total flux (photons/s) was measured within a 1 × 10 3 pixel circular region of interest using Living Image software (PerkinElmer).
Mouse model of a mixed S. aureus and P. aeruginosa wound infection mouse model. A mouse
model of a mixed full-thickness wound infection with S. aureus and P. aeruginosa was modified from a previously established model in which the S. aureus inoculum was 10-fold higher than the P. aeruginosa inoculum 60,61 , using the S. aureus AH4775 (luc) strain and the P. aeruginosa (lux) Xen41 strain (PerkinElmer). Briefly, C57BL/6 mice were anesthetized (2% isoflurane) and the dorsal backs were shaved and the skin was surgically prepped with povidone-iodine and 70% alcohol. A full thickness 6-mm punch biopsy (Acuderm) was used to create a circular excisional full-thickness wound and AH4775 (luc) (2 × 10 6 CFUs/10 µL) and Xen41 (lux) (2 × 10 5 CFUs/10 µL) were sequentially pipetted into the wound bed. In vivo BLI of AH4775 (luc) and Xen41 (lux) was performed on anesthetized mice 20 minutes after administration of D-Luciferin (150 mg/kg s.c.) on days 1, 3, and 7 with a 1 minute acquisition time at 37 °C using 670 nm and 520 nm emission filters. These specific filters were used because the luc and lux signals from the different bacteria could be spectrally unmixed, as there was no overlap of signals. On day 7, mice were euthanized and the wound tissue was homogenized and plated overnight to enumerate the ex vivo CFU, as described below.
Ex vivo cfU enumeration. For experiments with 1 × 10 6 CFU of AH4826 (lux + luc), mice were euthanized on day 3 and right and left kidneys, liver and heart were harvested and homogenized (Pro200 Series homogenizer; Pro Scientific) in 1 mL of PBS at 4 °C. Ex vivo CFU were counted after plating serially diluted organ tissue homogenates overnight on TSA plates. For lower limit of sensitivity and duration experiments with 1 × 10 6 CFU of AH4775 (luc), mice were euthanized at 16-hours and 3-weeks post-infection, respectively, and the right and left kidneys were separately harvested and homogenized (Pro200 Series homogenizer; Pro Scientific) in 1 mL of PBS at 4 °C and serially diluted homogenates were cultured overnight on TSA plates. D-Luciferin (30 mg/mL) was sprayed onto the plates and the plates were subsequently imaged in the (IVIS Lumina III) to enumerate the number of ex vivo CFU and to determine the percentage of CFU that still emitted a bioluminescent signal. For the mixed wound infection model with AH4775 (luc) and P. aeruginosa strain Xen41 (lux), mice were euthanized on day 7 post-infection and the wound tissue was excised with 8-mm punch biopsy tool (Acuderm). The excised tissue was homogenized (Pro200 Series homogenizer; Pro Scientific) in 1 mL of PBS at 4 °C and serially diluted homogenates were plated overnight on TSA plates. To distinguish between the CFU of AH4775 (luc) and Xen41, D-Luciferin (30 mg/mL) was sprayed onto the plates and the plates were subsequently imaged in the IVIS Lumina III using the 670 emission filter to identify and enumerate AH4775 (luc)-positive CFU and the 520 nm emission filter to identify Xen41 (lux)-positive CFU.
Rabbit model of S. aureus orthopaedic implant associated infection. This model of S. aureus
orthopaedic implant associated infection (OIAI) was performed as previously described 59 . Briefly, rabbits were anesthetized via intramuscular (i.m.) injection with ketamine and xylazine (25 mg/kg and 1.5 mg/kg respectively) (ZooPharm) and maintained with inhalation isoflurane (2%). Ophthalmic ointment (Optixcare eye lube) applied to the eyes. Sustained-release buprenorphine (ZooPharm) (0.2 mg/kg) and sustained-release meloxicam (Norbrook laboratories) (0.6 mg/dose) were given s.c. for analgesia. The right leg was shaved and ethanol and povidone-iodine (Betadine surgical scrub) (7.5%) were applied sequentially thrice. A midline incision over the patella was made followed by a medial parapatellar arthrotomy in which the patella was dislocated to visualize the femoral intercondylar notch. A 2-mm diameter hole was drilled and countersunk into the femoral medullary canal followed by bacterial inoculation with 1 × 10 4 CFU/10 μL PBS of AH4826 (lux + luc) into the intramedullary canal. An orthopedic-grade titanium locking peg (2 × 24 mm) (Zimmer Biomet) was inserted into the femoral medullary canal so that the end was flush with the articular surface. The patella was relocated to midline and surgical site was closed in a layered fashion using 3-0 Vicryl sutures. On post-surgical days 1, 4 and 7, in vivo BLI was performed on anesthetized rabbits (ketamine and xylazine i.m. and 2% isoflurane) ± administration of D-Luciferin (150 mg/kg s.c. given 15-25 minutes prior to imaging) for a 5 minute acquisition time at 37 °C (IVIS Lumina III). Total flux (photons/s) was measured within a 3 × 4 cm oval region of interest using Living Image software (PerkinElmer).
Statistics.
Data for multiple comparisons were calculated by 2-way ANOVA and data for single comparisons were compared using a 2-tailed Mann-Whitney U test. All statistical analyses were performed using Prism (GraphPad, La Jolla, CA). Data are presented as mean ± standard error of the mean (SEM) or geometric mean and values of P < 0.05 were considered significant.
